Experimental immune cell therapy tested against aggressive brain cancer
NCT ID NCT06355908
First seen Jan 22, 2026 · Last updated Apr 23, 2026 · Updated 13 times
Summary
This early-stage trial is testing whether modified immune cells called CAR-T cells can safely target and fight recurrent grade 4 brain tumors. The study involves 30 adults whose brain tumors have returned after standard treatments and whose tumors express a specific protein called IL13Rα2. Researchers will give different doses of these engineered immune cells to find the safest amount and see if they shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.